2-methylene-cyclobutanecarboxylic acid | 57822-22-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-methylene-cyclobutanecarboxylic acid
• 英文别名: 2-methylidenecyclobutane-1-carboxylic acid
• CAS: 57822-22-7
• 化学式: C₆H₈O₂
• mdl: MFCD19229109
• 分子量: 112.128
• InChiKey: ASRYRQIALCSPLM-UHFFFAOYSA-N

物化性质

• 沸点：
  211.6±19.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  亚甲基环丁烷 、 二氧化碳 在 正丁基锂 作用下， 生成 2-methylene-cyclobutanecarboxylic acid 、 2-(Cyclobuten-1-yl)acetic acid
  参考文献：
  名称：

  用氧代丙二酸二乙酯作为二氧化碳的亲烯当量进行烯羧化。烯丙基羧酸的合成

  摘要：

  在制备 une serie d'acides carboxyliques allyliques a partir des ocoxyliques par un processus en deux etapes 等价物 a: 1) une 反应 ene avec l'oxomalonate de diethyle conduisant a l'ester α-hydroxymalonique; 2) une bisdecarboxylation oxydante de ce dernier

  DOI：

  10.1021/ja00325a014

文献信息

• [EN] CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS<br/>[FR] COMPOSÉS CHIMIQUES UTILISÉS EN TANT QU'INHIBITEURS DE H-PGDS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018229629A1

  公开（公告）日：2018-12-20

  A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  根据本发明，化合物公式(I)中，R1、R2、R3、R4、X、Y和A的定义如所述。本发明的化合物是造血前列腺素D合酶（H-PGDS）的抑制剂，可用于治疗杜氏肌营养不良症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制H-PGDS活性和治疗相关疾病的方法。
• SPIROCYCLIC CYCLOPROPANOIC AMINO ACIDS - ANALOGUES OF GAMMA-AMINOBUTYRIC ACID, WITH LIMITED CONFORMATIONAL MOBILITY, AND DRUGS ON THE BASIS THEREOF
  申请人：Zapolsky, Maxim Eduardovich

  公开号：EP2682381A2

  公开（公告）日：2014-01-08

  The present invention relates to the field of organic and medicinal chemistry, and may also be used in applied medicine. The essence of the invention consists in that novel spirocyclic cyclopropanoic amino acids of general formula I, which are conformationally limited analogues of γ-aminobutyric acid, are proposed. In formula I, where n= 0-3 and Z=CR6R7, R1 - R7 are selected independently from a group consisting of hydrogen, (C1-C6)-alkyl and cyclo(C1-C6)-alkyl. These amino acids exhibit anti-psychotic, antidepressive, anti-spasmodic and anxiolytic properties. Drugs are also proposed for treating psychotic and depressive disorders, including for schizophrenia and affective dysfunctions; for treating convulsive conditions of varying genesis, including within the scope of epilepsy; for treating anxiety disorders of varying genesis, including generalized anxiety dysfunction and panic attacks; for treating somatoform dysfunctions, including persistent pain; for treating pain syndrome of varying genesis; for treating cognitive disorders, including attention and memory disorders of varying genesis.

  本发明涉及有机化学和药物化学领域，也可用于应用医药领域。本发明的实质在于提出了通式 I 的新型螺环环丙基氨基酸，它们是γ-氨基丁酸的构象受限类似物。在式 I 中，n= 0-3 和 Z=CR6R7 中，R1-R7 独立地选自氢、(C1-C6)-烷基和环(C1-C6)-烷基组成的组。这些氨基酸具有抗精神病、抗抑郁、抗痉挛和抗焦虑的特性。还提出了用于治疗精神病和抑郁症的药物，包括精神分裂症和情感功能障碍；用于治疗不同成因的抽搐症状，包括癫痫；用于治疗不同成因的焦虑症，包括广泛性焦虑功能障碍和惊恐发作；用于治疗躯体形式功能障碍，包括持续性疼痛；用于治疗不同成因的疼痛综合征；用于治疗认知障碍，包括不同成因的注意力和记忆力障碍。
• 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US11053234B2

  公开（公告）日：2021-07-06

  A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式 (I) 的化合物 其中 R、R1、R2、R3、Y、Y1、a、X 和 Z 如本文所定义。 本发明的化合物是造血前列腺素 D 合酶（H-PGDS）的抑制剂，可用于治疗杜氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制 H-PGDS 活性和治疗相关疾病的方法。
• Chemical compounds as H—PGDS inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US11149035B2

  公开（公告）日：2021-10-19

  A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式 (I) 的化合物 其中 R1、R2、R3、R4、X、Y 和 A 如本文所定义。 本发明的化合物是血液前列腺素 D 合酶（H-PGDS）的抑制剂，可用于治疗杜氏肌营养不良症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制 H-PGDS 活性和治疗与之相关疾病的方法。
• CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3638672A1

  公开（公告）日：2020-04-22